(Q54626855)

1 June 2018

title

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. (English)

1 reference

1 June 2018

0 references

L M Riesenbeck

1

1 reference

1 June 2018

S Bierer

2

1 reference

1 June 2018

I Hoffmeister

3

1 reference

1 June 2018

T Köpke

4

1 reference

1 June 2018

P Papavassilis

5

1 reference

1 June 2018

L Hertle

6

1 reference

1 June 2018

B Thielen

7

1 reference

1 June 2018

E Herrmann

8

1 reference

1 June 2018

publication date

14 December 2010

1 reference

1 June 2018

published in

World Journal of Urology

1 reference

1 June 2018

volume

29

1 reference

1 June 2018

issue

6

1 reference

1 June 2018

page(s)

807-813

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s00345-010-0627-2

exact match

0 references

cites work

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

EAU guidelines on renal cell carcinoma: the 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0627-2

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

21 January 2018

1 reference

12 December 2020

NCCN clinical practice guidelines in oncology: kidney cancer

1 reference

12 December 2020

Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

1 reference

12 December 2020

A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake

1 reference

12 December 2020

Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.

1 reference

12 December 2020

10.1007/S00345-010-0627-2

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018